Lexaria Bioscience Corp. (LEXX) stock
LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
$4.44+0.26 (+6.22%)
Close on Nov 13, 2026Market cap $110.06MP/E –Yield –
Lexaria Bioscience profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Lexaria Bioscience's profit margin for the twelve months ending May 31, 2026 was -3985.6%. For fiscal 2025 it was -1686.0%, against -1248.2% the year before. The highest annual figure on record is 1841.8% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | -1686.0% | −437.7 |
| FY2024 | Aug 31, 2024 | -1248.2% | +1698.1 |
| FY2023 | Aug 31, 2023 | -2946.4% | −100.1 |
| FY2022 | Aug 31, 2022 | -2846.3% | −2289.1 |
| FY2021 | Aug 31, 2021 | -557.2% | +740.4 |
| FY2020 | Aug 31, 2020 | -1297.6% | −3139.3 |
| FY2019 | Aug 31, 2019 | 1841.8% | +318.5 |
| FY2018 | Aug 31, 2018 | 1523.2% | +4555.1 |
| FY2017 | Aug 31, 2017 | -3031.9% | +104.9 |
| FY2016 | Aug 31, 2016 | -3136.8% | +10353.0 |
| FY2015 | Aug 31, 2015 | -13489.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | -7249.9% | −5779.9 |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | -1549.3% | +1051.6 |
| Q3 FY2025CQ2 2025 | May 31, 2025 | -2177.6% | −56.6 |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | -1559.3% | −1111.4 |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | -1470.0% | −690.4 |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | -2600.9% | +1430.5 |
| Q3 FY2024CQ2 2024 | May 31, 2024 | -2121.1% | +930.8 |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | -448.0% | +6034.6 |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | -779.6% | +1017.1 |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | -4031.5% | −2711.2 |
| Q3 FY2023CQ2 2023 | May 31, 2023 | -3051.9% | −662.2 |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | -6482.6% | −1830.8 |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | -1796.6% | +12563.3 |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | -1320.3% | +2477.5 |
| Q3 FY2022CQ2 2022 | May 31, 2022 | -2389.7% | −1131.9 |
| Q2 FY2022CQ1 2022 | Feb 28, 2022 | -4651.8% | −4856.6 |
| Q1 FY2022CQ4 2021 | Nov 30, 2021 | -14359.9% | −14119.7 |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -3797.7% | −2418.8 |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -1257.8% | +2560.3 |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | 204.8% | +2861.3 |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -240.2% | +8710.3 |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -1378.9% | −7087.4 |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -3818.1% | −1835.9 |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -2656.5% | +4856.1 |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -8950.5% | −5792.3 |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | 5708.4% | −6727.0 |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -1982.2% | +458.3 |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | -7512.6% | −6711.0 |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | -3158.1% | −809.0 |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | 12435.4% | +18167.1 |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -2440.4% | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -801.6% | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -2349.1% | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -5731.7% | – |
See a number that looks wrong?